Study Shows Cannabis Use Linked to Lung Inflammation and Emphysema

Nov.23.2022
Study Shows Cannabis Use Linked to Lung Inflammation and Emphysema
Scientists at the University of Ottawa have found that marijuana users have more respiratory inflammation and signs of emphysema than smokers.

Research shows that the source of the lung lobe image is Global Look Press.


Scientists at the University of Ottawa have found that individuals who use marijuana have more signs of respiratory inflammation and lung emphysema in their lungs compared to smokers. This research was published in the Radiology journal.


Scientists analyzed the results of chest computed tomography (CT) scans from 56 cannabis users, 57 non-smokers, and 33 smokers. The data was obtained from October 2005 to July 2020 in Ottawa, Canada.


Compared to non-smokers, CT scans of marijuana users show differing frequencies of signs of respiratory inflammation, such as emphysema, bronchial thickening, bronchial dilation, mucous obstruction, and cardiac nodules.


Consumers of marijuana are 93% more likely to suffer from chronic obstructive pulmonary disease (COPD) compared to non-smokers, while smokers who consume marijuana have a 67% increased frequency of smoking.


A study has found that 38% of marijuana users who participated in the study reported experiencing gynecomastia, a condition that causes pathological breast enlargement in males. Of those affected, 16% were non-smokers.


This study has limitations, as it was not able to clearly distinguish the consequences of smoking from those of using marijuana. Firstly, only 28 out of 56 patients provided information about their daily marijuana intake, with an average of 1.85 grams per day.


Furthermore, out of 56 marijuana consumers, 50 of them also smoke. The author calls for further research.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS and we cannot confirm the authenticity or accuracy of its content. The translation of this article is solely intended for industry-related research and communication.


Due to limitations in translation ability, the translated article may not fully reflect the original content. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign positions and statements.


Information compiled here is the property of the original media and authors. If there is any infringement, please contact us to request removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.